Please describe your proposed solution.
<u>Context.</u>
The DSCSA outlines requirements for enhanced drug distribution security, which include the steps to achieve interoperable, electronic tracing of products at the package level.
These requirements for enhanced drug distribution security go into effect on November 27, 2023.
The FDA sets forth enhanced drug distribution security requirements for trading partners, including adherence to standards established by FDA for the exchange of transaction information and transaction statements in a secure, interoperable, electronic manner and the verification of product at the package level.
<u> WHAT PRODUCTS DOES THIS SOLUTION ADDRESS?</u>
In general, a product is a prescription drug in a finished dosage form for administration to a patient without requiring substantial further manufacturing, such as capsules, tablets, and lyophilized products before reconstitution.
<u>WHAT TRANSACTIONS DOES THIS SOLUTION ADDRESS?</u>
In general, a transaction is defined as a transfer of product between persons in which a change of ownership occurs.
<u>THE SOLUTION.</u>
Create an interoperable system that could identify and trace prescription drugs without require a centralized system to hold the information.
An interoperable system means the ability to exchange transaction history, transaction information, and transaction statements accurately, efficiently, and consistently among trading partners; and for a subsequent purchaser’s system, process, or practice to successfully capture and maintain the transaction history, transaction information, and transaction statements, regardless of whether they are provided in a paper or electronic format.
The proposal consists of 3 stages:
1) System Architecture and Design.
I will create a MVP for a system for trading partners to exchange transaction information and transaction statements, which generally must include package level product identifiers for each package included in the transaction.with the following features:
- Processes in place to verify products at the package level.
- Processes in place to promptly respond with the transaction information and transaction statement for a product upon a request by the Secretary, in the event of a recall or for investigations of suspect or illegitimate product.
- Processes in place to facilitate the gathering of information needed to produce the transaction information for a product in the event of a request by the Secretary, on account of a recall or for suspect or illegitimate product.
- Iif the trading partner accepts saleable returns, have systems and processes in place to accept product and saleable returns if the trading partner can associate the saleable return product with the transaction information and transaction statement associated with that product.
In addition,this system must also utilize data standards that facilitate a uniform process or methodology for product tracing and ensure the protection of confidential commercial information and trade secrets to protect such information should not be limited to adhering to EPCIS, but should also include using individual system(s) and procedure(s), and business practices that ensure the confidentiality of such information.*
- This feature is not cover by this proposal, in the future I will explore solutions like midnight or encoins to protect sensible data.
2) Prototype Implementation.
This proposal aims to develop a ‘MVP’ representing a fully interoperable system for trading partners. Therefore, this proposal evaluates all architecture components in Cardano and applies a implementation in an experimental setting to ensure their implementation ability.
3) Testing: In order to evaluate the MVP , I will test using an example of the industry, at least simulation on the testnet. I did a little consultation on lidonation , I can see that 190 proposals have been approved in catalyst related to healthcare. I will contact some of them in order to participate and test the prototype.
After examining the results of the proposal, I'll spotlight important findings. Finally, I'll summarize the current limitations of the system and suggest recommendations for future steps.